More on CURN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.15 |
|
|||
| Open | $21.60 | ||||
| 52 Wk High | $25.00 | ||||
| 52 Wk Low | $11.41 | ||||
| Day High | $21.60 | ||||
| Day Low | $21.17 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,100 | ||||
- Curatis Increases Revenue Growth Guidance for 2026
- Currency Exchange International, Corp. (CURN) Reports Q2 EPS of $0.40
- Currency Exchange International, Corp. (CURN) Reports Q1 EPS of $0.32
- Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
- Currency Exchange renews share buyback program for up to 359,617 shares
- Correction to Currency Exchange International, Corp. Announcement of Renewal of Share Buyback Program and Automatic Securities Purchase Plan
- Currency Exchange International renews share buyback program
- Currency Exchange International, Corp. Announces Renewal of Share Buyback Program and Automatic Securities Purchase Plan
- Currency Exchange International Announces Adoption of Shareholder Rights Plan
- Curatis receives FDA approval to proceed with corticorelin phase 3 trial
Entities mentioned with CURN
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Stock Buyback | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Bankruptcy | View Related Stories »
- Show More...
